Xeris Biopharma Q4 product revenue beats analyst expectations, driven by higher patient demand

Xeris Biopharma Holdings

02/03/2026 12:08

Overview

Biopharmaceutical firm reported record Q4 revenue, beating analyst expectations

Net income for Q4 was $11.1 mln, compared to a net loss last year

Company expects 2026 revenue between $375 mln to $390 mln

Outlook

Xeris expects 2026 revenue between $375 mln and $390 mln

Company anticipates 2026 R&D expense to rise by $25 mln

Xeris forecasts 2026 SG&A expense to grow by $45 mln

Result Drivers

RECORLEV DEMAND - Recorlev net revenue increased by 100% in Q4 2025, driven by higher patient demand

GVOKE PRICING - Gvoke net revenue rose by 6% in Q4 2025 due to favorable net pricing

KEVEYIS DEMAND - Keveyis net revenue grew by 15% in Q4 2025, attributed to increased patient demand

Company press release: ID:nBw6df2Bwa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
Beat
$83.43 mln
$82.34 mln (5 Analysts)
Q4 EPS
$0.06
Q4 Net Income
$11.08 mln
Q4 Operating Income
$16.77 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $10.00, about 63.4% above its February 27 closing price of $6.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)